Announcement • Jun 15
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO XORTX Therapeutics Inc. had appointed Mika Grasso as co-CEO responsible for finance and public markets. Mr. Grasso, age 28, has served as a director of the Company since March 24, 2026. Mr. Grasso has served as an Investment Manager at a family office, where he has been responsible for sourcing and evaluating the fund’s direct investment and co-investment efforts. Previously, Mr. Grasso served as a Finance Associate at Zions Capital Markets from November 2023 until March 2025, as an Investment Banking Associate at Paulson Investment Company from February 2022 until November 2023, as an Analyst at Goldman Sachs from August 2021 to February 2022, and as an Analyst on the Real Assets Team at Power Systems Management from May 2020 to August 2021. Mr. Grasso received his MS in Finance, with a concentration in Investment Management, and his BS in Business Administration from the Leeds School of Business at the University of Colorado Boulder. Announcement • Jun 14
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange XORTX Therapeutics Inc. elected to voluntarily delist its common shares from the TSX Venture Exchange following a strategic review of dual-listing costs and regulatory requirements. The company expects benefits including lower exchange, legal and accounting fees, streamlined financing and greater management focus on advancing its XRx-026 gout program. Shares will continue trading on Nasdaq, no shareholder action is required, and XORTX remains a reporting issuer in Alberta, British Columbia and Ontario. Voluntary TSXV delisting expected to cut duplicative exchange fees. Company anticipates reduced legal and accounting expenses. Management expects optimized financing initiatives post-delisting. Delisting aims to free management focus for XRx-026 gout program. Nasdaq listing preserved, with full trading access for all shareholders. Company remains a reporting issuer in Alberta, British Columbia and Ontario. Common shares will no longer be listed on the TSX Venture Exchange. Canadian investors lose a domestic exchange venue for trading XRTX. The voluntary delisting from the TSXV was approved by the Company's Board of Directors. In accordance with TSXV policies, shareholder approval is not required as the Company’s common shares are listed on an acceptable alternative market. XORTX will continue to be a reporting issuer under applicable securities laws in Alberta, British Columbia and Ontario. Announcement • May 19
XORTX Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $5 million. XORTX Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 183,577
Price\Range: $1.88
Discount Per Security: $0.0752
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 2,475,997 
